Publications by authors named "Dorie Sher"

Claim this Profile
A
A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis.
Chenyu Lin, Anand A Patel, Dezheng Huo, Theodore Karrison, Koen van Besien, Dorie Sher

Blood Adv· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.
Xavier Poiré, Barry K Moser, Robert E Gallagher, Kristina Laumann, Clara D Bloomfield, Dorie Sher

Leuk Lymphoma· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a next-generation sequencing assay for clinical molecular oncology.
Catherine E Cottrell, Hussam Al-Kateb, Andrew J Bredemeyer, Eric J Duncavage, David H Spencer, Dorie A Sher

J Mol Diagn· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.
Robert E Gallagher, Barry K Moser, Janis Racevskis, Xavier Poiré, Clara D Bloomfield, Dorie A Sher

Blood· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909.
Hongtao Liu, Jeffrey L Johnson, Greg Koval, Greg Malnassy, Dorie Sher

Haematologica· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012).
Marilyn L Slovak, Victoria Bedell, Danika Lew, Kathy S Albain, Georgiana K Ellis, Dorie Sher

Breast Cancer Res Treat· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).
Ivan M Borrello, Hyam I Levitsky, Wendy Stock, Dorie Sher, Lu Qin

Blood· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia.
Olatoyosi M Odenike, Serhan Alkan, Dorie Sher, John E Godwin, Dezheng Huo

Clin Cancer Res· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.
Melinda K Gordon, Dorie Sher, Theodore Karrison, Partow Kebriaei, Karen Chuang

Leuk Lymphoma· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.
Wendy Stock, Daohai Yu, Ted Karrison, Dorie Sher, Richard M Stone

Int J Oncol· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assaying Bcr-Abl kinase activity and inhibition in whole cell extracts by phosphorylation of substrates immobilized on agarose beads.
Ding Wu, Evan Nair-Gill, Dorie A Sher, Laurie L Parker, Jennifer M Campbell

Anal Biochem· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
Guido Marcucci, Wendy Stock, Guowei Dai, Rebecca B Klisovic, Shujun Liu, Dorie A Sher

J Clin Oncol· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis